Quinisol - Instructions For Use, Tablets, Price, Analogs, Reviews

Table of contents:

Quinisol - Instructions For Use, Tablets, Price, Analogs, Reviews
Quinisol - Instructions For Use, Tablets, Price, Analogs, Reviews

Video: Quinisol - Instructions For Use, Tablets, Price, Analogs, Reviews

Video: Quinisol - Instructions For Use, Tablets, Price, Analogs, Reviews
Video: Review: MEKO 2-in-1 Stylus (2nd Gen) 2023, March


Quinisol: instructions for use and reviews

  1. 1. Release form and composition
  2. 2. Pharmacological properties
  3. 3. Indications for use
  4. 4. Contraindications
  5. 5. Method of application and dosage
  6. 6. Side effects
  7. 7. Overdose
  8. 8. Special instructions
  9. 9. Application during pregnancy and lactation
  1. 10. Use in childhood
  2. 11. For violations of liver function
  3. 12. Use in the elderly
  4. 13. Drug interactions
  5. 14. Analogs
  6. 15. Terms and conditions of storage
  7. 16. Terms of dispensing from pharmacies
  8. 17. Reviews
  9. 18. Price in pharmacies

Latin name: Kvinizol

ATX code: J01XD03

Active ingredient: Ornidazole (Ornidazole)

Manufacturer: We-Em-Ji Pharmaceuticals Pvt. Ltd. (VMG Pharmaceuticals Pvt. Ltd.) (India); LLC "Rozlex Pharm" (Russia)

Description and photo update: 2019-12-07

Prices in pharmacies: from 229 rubles.


Film-coated tablets, Quinisol
Film-coated tablets, Quinisol

Quinisol is an antiprotozoal and antimicrobial agent.

Release form and composition

  • film-coated tablets: biconvex, round, the inner layer in the cross section and the film shell - almost white or white (10 pcs. in a blister of aluminum foil and polyvinyl chloride; in a cardboard box 1 or 2 blisters);
  • solution for infusion: clear, colorless liquid (100 ml in a bottle made of low density polyethylene, sealed with a lid made of the same material; in a cardboard box 1 bottle).

Each pack also contains instructions for the use of Quinisol.

Composition of 1 tablet:

  • active substance: ornidazole - 500 mg;
  • additional components: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, starch, talc;
  • film shell: macrogol, hypromellose, titanium dioxide, talc.

100 ml of solution for infusion contains:

  • active substance: ornidazole - 500 mg;
  • additional components: hydrochloric acid, sodium chloride, water for injection.

Pharmacological properties


Ornidazole is an antimicrobial and antiprotozoal drug from the group of 5-nitroimidazole derivatives. The action of the active substance is aimed at biochemical recovery by intracellular transport proteins of anaerobic bacteria and protozoa 5-nitro group of ornidazole. After restoration, the latter begins to interact with the DNA cells of these microorganisms, suppressing the production of their nucleic acids and causing the death of bacteria.

Quinisol is active against Giardia lamblia (Giardia intestinalis), Trichomonas vaginalis, Entamoeba histolytica, as well as some anaerobic bacteria - Fusobacterium spp., Clostridium spp., Bacteroides spp. (including Bacteroides fragilis, Bacteroides ovatus, Bacteroides distasonis, Bacteroides vulgatus, Bacteroides thetaiotaomicron) and anaerobic cocci Peptostreptococcus spp.

Aerobic microorganisms are resistant to ornidazole.


After oral administration of Quinisol, the active substance is rapidly absorbed in the gastrointestinal tract (GIT), by about 90%. In plasma, the maximum concentration of ornidazole is reached within 3 hours after administration. About 13-15% bind to plasma proteins. Quinisole is distributed in most tissues, penetrates into the cerebrospinal fluid and other body fluids, crosses the placenta and the blood-brain barrier, and is detected in breast milk. Plasma concentrations of ornidazole are determined in the range of 6–36 mg / l. The cumulation coefficient after repeated administration at a dose of 500/1000 mg every 12 hours is 1.5–2.5.

Ornidazole is metabolized in the liver with the formation, mainly, of 2-hydroxymethyl- and α-hydroxymethylmetabolites. The resulting metabolites show less activity against anaerobic bacteria and Trichomonas vaginalis than the unchanged base substance. The half-life (T 1/2) is about 13 hours. After a single oral administration, 85% of the dose is excreted from the body during the first 5 days, mainly in the form of metabolites through the intestines and kidneys. Approximately 5% of the administered dose is excreted unchanged by the kidneys and 20–25% - by the intestines.

Indications for use

Quinisol is indicated for the treatment of infections caused by bacteria and protozoa sensitive to ornidazole.

Film-coated tablets are prescribed for the treatment of the following diseases / conditions:

  • trichomoniasis (infections of the genitourinary system in women and men, excited by Trichomonas vaginalis;
  • amebiasis (all intestinal infections associated with Entamoeba histolytica, including extraintestinal forms of amebiasis, amoebic dysentery, especially amoebic liver abscess);
  • giardiasis;
  • anaerobic infections during gynecological interventions and during operations on the colon (for prophylaxis).

Indications for the use of Quinisol solution for infusion are:

  • infections excited by anaerobic microbes (peritonitis, septicemia, osteomyelitis, meningitis, infections of the pelvic organs, soft tissue and skin infections, postoperative wound infections), including as part of a combination treatment;
  • intestinal and hepatic amebiasis in severe form;
  • anaerobic infections during surgical interventions on the abdominal and pelvic organs (for prophylaxis).



  • age up to 3 years and body weight less than 20 kg - for tablets;
  • blood cell abnormalities and pathological changes in the blood;
  • organic diseases of the central nervous system;
  • I trimester of pregnancy;
  • lactation period;
  • hypersensitivity to any of the constituents of the drug and to other derivatives of nitroimidazole.

Relative (you should use Quinisol with extreme caution): age over 3 years and body weight over 20 kg in children (for tablets), II – III trimesters of pregnancy, liver dysfunction, alcoholism, old age.

Quinisol, instructions for use: method and dosage

Film-coated tablets

In tablets, Quinisol is taken orally after meals. The drug should be taken with a little water.

Recommended dosage regimen depending on indications:

  • trichomoniasis: children weighing more than 35 kg and adults - 500 mg (1 tablet) 2 times a day, morning and evening, course - 5 days; to prevent possible re-infection at the same time, the sexual partner must receive the same course of treatment; children weighing 20–35 kg - 25 mg / kg 1 time per day for 5 days;
  • amoebic dysentery: children weighing more than 35 kg and adults weighing no more than 60 kg - 1500 mg (3 tablets) once a day in the evening, with a body weight of more than 60 kg - 1000 mg (2 tablets) 2 times per day, morning and evening; children after 3 years with a body weight of 20–35 kg - 40 mg / kg once a day, the course of treatment in all cases is 3 days;
  • all forms of amebiasis: for children with a body weight of over 35 kg and for adults - 500 mg (1 tablet) 2 times a day, morning and evening; children over 3 years old with a body weight of 20–35 kg - 25 mg / kg once a day; the course of treatment in all cases is 5-10 days;
  • giardiasis: children weighing over 35 kg and adults - 1500 mg (3 tablets) once a day after dinner, children with a body weight of 20–35 kg - 40 mg / kg at the same frequency of administration, course - 1– 2 days;
  • prevention of infections caused by anaerobic bacteria during operations: 1-2 hours before surgical treatment, 500-1000 mg (1-2 tablets), after surgery, 500 mg 2 times a day for 3-5 days.

Solution for infusion

Quinisol is administered by intravenous (IV) drip. Infusion infusion is indicated in the case of a severe course of infection, as well as when it is impossible to take the oral form of the drug.

The rate of intravenous drip is 5 ml per minute, the interval between infusions is 12 hours.

The course of therapy is set individually, taking into account the clinical condition of the patient. According to the indications, depending on the nature and severity of the infection, the patient should be transferred to maintenance therapy with oral medications of ornidazole as soon as possible.

Recommended dosing regimen of Quinisol:

  • intestinal amebiasis and amoebic liver abscess: for adults - at an initial dose of 500–1000 mg, with further administration every 12 hours at 500 mg; children - 2-30 mg / kg per day; course - 3-6 days;
  • anaerobic bacterial infections: for adults - at an initial dose of 500–1000 mg, with a further transition to infusions every 12 hours at 500 mg; children - with an interval of 12 hours at a dose of 10 mg / kg; course - 5-10 days;
  • prevention of infections caused by anaerobic bacteria: once 500–1000 mg 30 minutes before surgery.

Side effects

  • blood and lymphatic system: infrequently - neuropathy, suppression of bone marrow hematopoiesis;
  • nervous system: often - dizziness, drowsiness, fatigue, headache; rarely - tremor, temporary loss of consciousness, impaired coordination of movement, muscle rigidity, sensory / mixed peripheral neuropathy, convulsions; extremely rarely - a change in taste;
  • immune system: infrequently - skin rash, itching, urticaria, hypersensitivity reactions, Quincke's edema;
  • digestive system: very often - metallic taste in the mouth, nausea, vomiting; rarely - loss of appetite, diarrhea, changes in the activity of liver enzymes;
  • violations at the injection site: pain at the injection site.


Symptoms of ornidazole overdose may be aggravation of dose-dependent adverse reactions.

In this condition, symptomatic treatment is carried out, in case of the development of seizures, diazepam is prescribed. The specific antidote is unknown.

special instructions

The solution for infusion should not be mixed with other drugs in the same bottle.

In the treatment of mixed infections, Quinisol in the form of an infusion solution can be used in combination with oral antibiotics.

During the period of treatment, there may be an aggravation of the course of diseases of the peripheral nervous system. If dizziness, ataxia, symptoms of peripheral neuropathy, confusion occur, the use of Quinisol must be suspended.

In patients undergoing hemodialysis treatment, a shortened T 1/2 is recorded, and therefore a dose adjustment of ornidazole may be necessary.

When using lithium preparations against the background of ornidazole therapy, it is necessary to monitor the plasma content of lithium, electrolytes and creatinine in the blood.

Influence on the ability to drive vehicles and complex mechanisms

During therapy with Quinisol, you should not drive a car or engage in other activities that require increased concentration of attention and speed of psychomotor reactions.

Application during pregnancy and lactation

Quinisol therapy is contraindicated in the first trimester of pregnancy and during breastfeeding. Ornidazole in the experiment did not show teratogenic or toxic effects on the fetus. However, in pregnant women, controlled studies have not been carried out, therefore, the use of ornidazole in the II and III trimesters of pregnancy is allowed only when the expected benefit of treatment for the mother outweighs the potential threat to the fetus.

If it is necessary to prescribe Quinisol during lactation, it is required to refuse breastfeeding. Breastfeeding can be resumed no earlier than 48 hours after using the last dose of ornidazole.

Pediatric use

For patients under 3 years of age and with a body weight of less than 20 kg, Quinisol tablets are contraindicated. Children over 3 years old and with a body weight of more than 20 kg should be used with caution.

For violations of liver function

In the presence of functional disorders of the liver, Quinisol should be used with caution.

Use in the elderly

Elderly patients are advised to treat with the drug with caution.

Drug interactions

  • hepatic enzyme inducers, including phenobarbital: lower T 1/2 of ornidazole from blood plasma;
  • indirect anticoagulants of the coumarin series: ornidazole enhances the effectiveness of these funds, which may require a change in their dose;
  • vecuronium bromide: combined use with Quinisol prolongs its muscle relaxant effect;
  • inhibitors of liver microsomal enzymes, including cimetidine: increase the plasma concentration of ornidazole;
  • ethanol: the incompatibility of ornidazole with this alcohol is not detected, since, in contrast to other nitroimidazole derivatives, the drug does not inhibit the activity of aldehyde dehydrogenase.


Quinisol analogues are Dazolik, Gayro, Ornidazole, Ornidazole-OBL, Ornidazol-Vero, Ornisid, Tiberal, Ornisid Forte, etc.

Terms and conditions of storage

Store in a place protected from moisture and light, out of the reach of children, at a temperature not exceeding 25 ° C.

The shelf life is 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews of Quinisol

The few reviews about Quinisol found on specialized sites, as a rule, confirm its effectiveness in the treatment of trichomoniasis, giardiasis and amebiasis in children and adults. At the same time, many patients complain of the development of such undesirable reactions as weakness, dizziness, drowsiness, lack of appetite and nausea during treatment. Therefore, the use of Quinisol is recommended only as directed by a doctor.

Price for Quinisol in pharmacies

The price of Quinisol, 500 mg film-coated tablets, can be 210–250 rubles. per package containing 10 pcs.

Quinisol: prices in online pharmacies

Drug name



Quinisol 500 mg film-coated tablets 10 pcs.

229 r


Anna Kozlova
Anna Kozlova

Anna Kozlova Medical journalist About the author

Education: Rostov State Medical University, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!

Popular by topic